Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2012

Global Markets Direct, August 2012, Pages: 143

Metastatic Renal Cell Carcinoma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2012', provides an overview of the Metastatic Renal Cell Carcinoma therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma. 'Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Metastatic Renal Cell Carcinoma.
- A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Metastatic Renal Cell Carcinoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Metastatic Renal Cell Carcinoma Therapeutic Products under Development, Key Players in Metastatic Renal Cell Carcinoma Therapeutics, Metastatic Renal Cell Carcinoma Pipeline Overview, Metastatic Renal Cell Carcinoma Pipeline, Metastatic Renal Cell Carcinoma Pipeline Assessment

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Metastatic Renal Cell Carcinoma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Metastatic Renal Cell Carcinoma 9
Metastatic Renal Cell Carcinoma Therapeutics under Development by Companies 11
Metastatic Renal Cell Carcinoma Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Metastatic Renal Cell Carcinoma Therapeutics – Products under Development by Companies 19
Metastatic Renal Cell Carcinoma Therapeutics – Products under Investigation by Universities/Institutes 21
Companies Involved in Metastatic Renal Cell Carcinoma Therapeutics Development 24
Bristol-Myers Squibb Company 24
Amgen Inc. 25
Eli Lilly and Company 26
Novartis AG 27
Eisai Co., Ltd. 28
Pfizer Inc. 29
Taiho Pharmaceutical Co., Ltd. 30
Novartis Pharmaceuticals Corporation 31
Bionomics Limited 32
Angiogene Pharmaceuticals Ltd. 33
Cerulean Pharma, Inc. 34
AVEO Pharmaceuticals, Inc. 35
Abramson Cancer Center 36
Metastatic Renal Cell Carcinoma – Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
E7080 - Drug Profile 43
Afinitor - Drug Profile 45
IMC-1121B - Drug Profile 48
ZD6126 - Drug Profile 50
BNC105P + Afinitor - Drug Profile 52
Dalteparin + SU11248 - Drug Profile 53
LBH589 + RAD001 - Drug Profile 54
Sunitinib + Gemcitabine - Drug Profile 55
Tarceva + Rapamune - Drug Profile 57
Avastin - Drug Profile 58
Sutent - Drug Profile 60
OSI-774 - Drug Profile 61
Tivozanib + Torisel - Drug Profile 63
CVX 060 - Drug Profile 65
AMG 386 + Sunitinib - Drug Profile 66
Bevacizumab + Everolimus - Drug Profile 68
PEG Intron + Sargramostim + Thalidomide - Drug Profile 69
PEG Intron + Sargramostim + Thalidomide - Drug Profile 70
PEG Intron + Sargramostim + Thalidomide - Drug Profile 72
Gemcitabine + CPT-11 - Drug Profile 73
Pazopanib - Drug Profile 75
Enzastaurin + Sunitinib - Drug Profile 76
Sorafenib - Drug Profile 77
Capecitabine + Gemcitabine + Bevacizumab - Drug Profile 78
BAY 43-9006 - Drug Profile 80
Velcade + Sorafenib - Drug Profile 82
RAD001 - Drug Profile 83
RAD001 + Bevacizumab - Drug Profile 85
Temsirolimus - Drug Profile 86
Sunitinib - Drug Profile 87
Pentostatin + Cyclophosphamide + Sirolimus + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 88
E7080 + Everolimus - Drug Profile 90
Sunitinib - Drug Profile 91
Interleukin-2 + Interferon Alfa + Fluorouracil - Drug Profile 92
Celecoxib + Recombinant Interferon Alfa-2b - Drug Profile 94
Vinorelbine + Estramustine + Prednisone - Drug Profile 96
Aldesleukin + Entinostat - Drug Profile 97
Torisel + Avastin - Drug Profile 98
Interferon + BAY 43-9006 - Drug Profile 99
Interferon + BAY 43-9006 - Drug Profile 101
Aldesleukin + BAY 43-9006 - Drug Profile 103
Interferon Alpha-1b - Drug Profile 104
Pazopanib + Bevacizumab - Drug Profile 105
Cisplatin + Gemcitabine - Drug Profile 106
Gemcitabine + Doxil - Drug Profile 107
SU011248 - Drug Profile 108
Immuneron - Drug Profile 110
S-1 + Sorafenib - Drug Profile 111
BKM-120 + Avastin - Drug Profile 112
Sunitinib - Drug Profile 113
Sorafenib - Drug Profile 114
Bevacizumab + Interferon Alfa-2a - Drug Profile 115
LY2510924 + Sunitinib - Drug Profile 116
BMS-936558 + Sunitinib - Drug Profile 117
Afinitor + BEZ235 - Drug Profile 118
Hydroxychloroquine + RAD001 - Drug Profile 120
PF-04856884 + Axitinib - Drug Profile 121
CRLX101 + Avastin - Drug Profile 122
Metastatic Renal Cell Carcinoma Therapeutics – Drug Profile Updates 123
Metastatic Renal Cell Carcinoma Therapeutics – Discontinued Products 130
Metastatic Renal Cell Carcinoma Therapeutics - Dormant Products 131
Metastatic Renal Cell Carcinoma – Product Development Milestones 135
Featured News & Press Releases 135
Appendix 138
Methodology 138
Coverage 138
Secondary Research 138
Primary Research 138
Expert Panel Validation 138
Contact Us 139
Disclaimer 139

List of Tables
Number of Products Under Development for Metastatic Renal Cell Carcinoma, H2 2012 13
Products under Development for Metastatic Renal Cell Carcinoma – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Investigation by Universities/Institutes, H2 2012 18
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 19
Comparative Analysis by Late Stage Development, H2 2012 20
Comparative Analysis by Mid Clinical Stage Development, H2 2012 21
Comparative Analysis by Early Clinical Stage Development, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Development by Companies, H2 2012 (Contd..1) 24
Products under Investigation by Universities/Institutes, H2 2012 25
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 26
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 27
Bristol-Myers Squibb Company, H2 2012 28
Amgen Inc., H2 2012 29
Eli Lilly and Company, H2 2012 30
Novartis AG, H2 2012 31
Eisai Co., Ltd., H2 2012 32
Pfizer Inc., H2 2012 33
Taiho Pharmaceutical Co., Ltd., H2 2012 34
Novartis Pharmaceuticals Corporation, H2 2012 35
Bionomics Limited, H2 2012 36
Angiogene Pharmaceuticals Ltd., H2 2012 37
Cerulean Pharma, Inc., H2 2012 38
AVEO Pharmaceuticals, Inc., H2 2012 39
Abramson Cancer Center, H2 2012 40
Assessment by Monotherapy Products, H2 2012 41
Assessment by Combination Products, H2 2012 42
Assessment by Stage and Route of Administration, H2 2012 44
Assessment by Stage and Molecule Type, H2 2012 46
Metastatic Renal Cell Carcinoma Therapeutics – Drug Profile Updates 127
Metastatic Renal Cell Carcinoma Therapeutics – Discontinued Products 134
Metastatic Renal Cell Carcinoma Therapeutics – Dormant Products 135
Metastatic Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..1) 136
Metastatic Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..2) 137
Metastatic Renal Cell Carcinoma Therapeutics – Dormant Products (Contd..3) 138

List of Figures
Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2012 13
Products under Development for Metastatic Renal Cell Carcinoma – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 17
Late Stage Products, H2 2012 20
Mid Clinical Stage Products, H2 2012 21
Early Clinical Stage Products, H2 2012 22
Assessment by Monotherapy Products, H2 2012 41
Assessment by Combination Products, H2 2012 42
Assessment by Route of Administration, H2 2012 43
Assessment by Stage and Route of Administration, H2 2012 44
Assessment by Molecule Type, H2 2012 45
Assessment by Stage and Molecule Type, H2 2012 46

Customers who bought this item also bought

• Renal Cell Carcinoma (Event Driven)
• Stroke – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• HIV-1 Infection – Pipeline Review, H1 2013
• Chemotherapy Effects – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Major Depressive Disorder – Pipeline Review, H1 2013
• Fungal Infections – Pipeline Review, H1 2013
• Natural Killer Cell Lymphomas – Pipeline Review, H1 2013